Is the US prepared to deal with another pandemic or widespread health crisis?

Leans no

Assessing the readiness of the United States to handle another pandemic or widespread health crisis reveals a highly fragmented landscape. While the nation’s scientific and technological tools are vastly more advanced than they were in 2020, its institutional infrastructure, funding stability, and public trust have significantly deteriorated.

A comprehensive evaluation of the strengths, weaknesses, and real-world stress tests shaping U.S. pandemic preparedness highlights key areas of readiness and vulnerability:

1. The Strengths: Advanced Technology and Early Detection

The U.S. has made massive strides in its scientific arsenal, particularly in how it detects and develops countermeasures for emerging threats:

•Next-Generation Vaccine Platforms: Because of the infrastructure built during COVID-19, the U.S. has highly mature mRNA and platform technologies. If a new pathogen emerges, scientists can design, test, and manufacture targeted vaccines in a fraction of the time it took pre-2020.

•Wastewater Surveillance: The National Wastewater Surveillance System (NWSS) has emerged as one of the most successful public health innovations. By testing sewage, health agencies can detect spikes in pathogens (such as COVID-19, Mpox, seasonal flu, and measles) at the community level weeks before people show up in emergency rooms.

•The 100 Days Mission: The U.S. remains a key contributor to global initiatives aimed at developing diagnostics, therapeutics, and vaccines within 100 days of identifying a pandemic threat.

2. The Weaknesses: Legislative Gridlock and Funding Instability

Despite these technological leaps, the legal and financial foundations of U.S. biosecurity are highly unstable:

•The Expiration of PAHPA: The Pandemic and All-Hazards Preparedness Act (PAHPA)—the legislative bedrock that authorizes the Strategic National Stockpile (SNS) and the Biomedical Advanced Research and Development Authority (BARDA)—expired in late 2023. Congress has failed to pass a long-term, five-year reauthorization.

•Piecemeal Funding: Because PAHPA remains stalled in Congress due to political disagreements over scope and drug pricing, key biosecurity programs are being funded through temporary, short-term continuing resolutions. This lack of long-term financial certainty makes it difficult for agencies to sign multi-year contracts with pharmaceutical companies for vaccine development and stockpile maintenance.

3. Institutional Challenges: Workforce Depletion and Siloed Agencies

The agencies tasked with leading a pandemic response are structurally weaker than they were prior to COVID-19:

•Workforce Burnout and Cuts: The public health workforce has experienced severe depletion. Years of intense political pressure, harassment of local health officials, and administrative budget cuts have led to massive staff shortages. For example, former officials have warned that the CDC has faced significant workforce losses—up to 25% to 30%—and a high volume of leadership vacancies.

•Lack of Centralized Coordination: A Government Accountability Office (GAO) assessment highlighted that the U.S. still lacks a centralized authority to seamlessly coordinate surveillance across different federal departments. When diseases jump from animals to humans (zoonotic spillovers), the split between the USDA (which monitors animals) and HHS/CDC (which monitor humans) often results in fragmented, slow-moving data sharing.

4. The Societal Barrier: Erosion of Public Trust

Perhaps the greatest vulnerability is not scientific, but social:

•Vaccine Hesitancy: Public trust in health authorities and childhood vaccines has dropped. This erosion of trust has led to a resurgence of entirely preventable diseases; U.S. measles cases have reached their highest levels in over three decades.

•Resistance to Health Guidance: In the event of another pandemic, implementing basic public health mitigation measures (such as testing, quarantine, and masking) would likely face immediate, deep political polarization and public resistance, rendering government guidelines far less effective.

5. The Real-World Test: The H5N1 Avian Flu Response

The ongoing management of H5N1 Avian Influenza serves as a live-action stress test of U.S. preparedness:

•Since 2024, H5N1 has spread widely among poultry and dairy cows, resulting in dozens of human cases among agricultural workers.

•While agencies successfully tracked the virus's genetics and began preparing candidate vaccines, the response has revealed familiar cracks: health departments have struggled to convince dairy farmers to allow testing on their herds, and agricultural workers have been highly reluctant to participate in monitoring due to economic fears and a lack of trust in government officials. This has left public health agencies with blind spots regarding how widely the virus is actually spreading.

Conclusion

Is the United States prepared? Scientifically, yes; operationally and politically, no.

If a new, highly lethal pathogen were to emerge tomorrow, the U.S. could design a vaccine in record time. However, the nation would likely struggle to manufacture and distribute it smoothly, convince a skeptical public to take it, or coordinate a unified response across fractured state and federal agencies. Until Congress reauthorizes PAHPA, public health workforces are rebuilt, and trust is restored, the U.S. remains highly vulnerable to the next major health crisis.

Citations (14)

1ghtcoalition.orgNonprofits and think tanks
ghtcoalition.org
Backs: “The Strengths: Advanced Technology and Early Detection. The U.S. has made massive strides in its scientific arsenal, particularly in how it detects and develops countermeasures for emerging threats: Next-Generation Vaccine Platforms: Because of the infrastructure built during COVID-19, the U.S. has highly mature mRNA…”
evidence, article, points to yes. Claim: US has mature mRNA and platform technologies from COVID-19 infrastructure enabling faster vaccine development.
2asm.orgNonprofits and think tanks
asm.org
Backs: “Wastewater Surveillance: The National Wastewater Surveillance System (NWSS) has emerged as one of the most successful public health innovations. By testing sewage, health agencies can detect spikes in pathogens (such as COVID-19, Mpox, seasonal flu, and measles) at the community level weeks before people show up in…”
evidence, article, points to yes. Claim: National Wastewater Surveillance System is a successful innovation detecting pathogen spikes before ER visits.
3theindependentpanel.orgNonprofits and think tanks
theindependentpanel.org
Backs: “The 100 Days Mission: The U.S. remains a key contributor to global initiatives aimed at developing diagnostics, therapeutics, and vaccines within 100 days of identifying a pandemic threat.”
attribution, official document, points to yes. Claim: US contributes to global 100 Days Mission for diagnostics, therapeutics and vaccines.
4bio.newsNews and media
bio.news
Backs: “Congress has failed to pass a long-term, five-year reauthorization. Piecemeal Funding: Because PAHPA remains stalled in Congress due to political disagreements over scope and drug pricing, key biosecurity programs are being funded through temporary, short-term continuing resolutions.”
evidence, article, points to no. Claim: PAHPA expired in 2023 and Congress has failed to pass a long-term reauthorization.
5astho.orgNonprofits and think tanks
astho.org
Backs: “Piecemeal Funding: Because PAHPA remains stalled in Congress due to political disagreements over scope and drug pricing, key biosecurity programs are being funded through temporary, short-term continuing resolutions. This lack of long-term financial certainty makes it difficult for agencies to sign multi-year…”
evidence, article, points to no. Claim: PAHPA stalled over political disagreements, so programs run on short-term continuing resolutions.
6premierinc.comCompanies
premierinc.com
Backs: “This lack of long-term financial certainty makes it difficult for agencies to sign multi-year contracts with pharmaceutical companies for vaccine development and stockpile maintenance.”
evidence, article, points to no. Claim: Lack of long-term funding makes multi-year pharmaceutical contracts for vaccines and stockpiles difficult.
7pandorareport.orgNonprofits and think tanks
pandorareport.org
Backs: “Institutional Challenges: Workforce Depletion and Siloed Agencies. The agencies tasked with leading a pandemic response are structurally weaker than they were prior to COVID-19: Workforce Burnout and Cuts: The public health workforce has experienced severe depletion. Years of intense political pressure, harassment of…”
evidence, article, points to no. Claim: Public health workforce has experienced severe depletion from pressure, harassment and budget cuts.
8bipartisanpolicy.orgNonprofits and think tanks
bipartisanpolicy.org
Backs: “Institutional Challenges: Workforce Depletion and Siloed Agencies. The agencies tasked with leading a pandemic response are structurally weaker than they were prior to COVID-19: Workforce Burnout and Cuts: The public health workforce has experienced severe depletion. Years of intense political pressure, harassment of…”
evidence, article, points to no. Claim: Public health workforce depletion makes agencies structurally weaker than before COVID-19.
9youtube.comSocial media and video
youtube.com
Backs: “Years of intense political pressure, harassment of local health officials, and administrative budget cuts have led to massive staff shortages. For example, former officials have warned that the CDC has faced significant workforce losses—up to 25% to 30%—and a high volume of leadership vacancies.”
evidence, social or video, points to no. Claim: Harassment, political pressure and budget cuts caused staff shortages, including CDC workforce losses.
10gao.govGovernment
gao.gov
Backs: “Lack of Centralized Coordination: A Government Accountability Office (GAO) assessment highlighted that the U.S. still lacks a centralized authority to seamlessly coordinate surveillance across different federal departments. When diseases jump from animals to humans (zoonotic spillovers), the split between the USDA…”
evidence, official document, points to no. Claim: GAO found the US lacks a centralized authority to coordinate surveillance across federal departments.
11nih.govGovernment
nih.gov
Backs: “When diseases jump from animals to humans (zoonotic spillovers), the split between the USDA (which monitors animals) and HHS/CDC (which monitor humans) often results in fragmented, slow-moving data sharing. ---. 4.”
evidence, article, points to no. Claim: USDA and HHS/CDC split causes fragmented, slow data sharing on zoonotic spillovers.
12tfah.orgNonprofits and think tanks
tfah.org
Backs: “The Real-World Test: The H5N1 Avian Flu Response. The ongoing management of H5N1 Avian Influenza serves as a live-action stress test of U.S. preparedness: Since 2024, H5N1 has spread widely among poultry and dairy cows, resulting in dozens of human cases among agricultural workers.”
evidence, article, points to no. Claim: H5N1 response serves as a stress test of US preparedness.
13cdc.govGovernment
cdc.gov
Backs: “The Real-World Test: The H5N1 Avian Flu Response. The ongoing management of H5N1 Avian Influenza serves as a live-action stress test of U.S. preparedness: Since 2024, H5N1 has spread widely among poultry and dairy cows, resulting in dozens of human cases among agricultural workers. While”
evidence, official document, points to no. Claim: H5N1 spread among poultry and dairy cows, causing dozens of human cases among agricultural workers.
14aao.orgNonprofits and think tanks
aao.org
Backs: “The Real-World Test: The H5N1 Avian Flu Response. The ongoing management of H5N1 Avian Influenza serves as a live-action stress test of U.S. preparedness: Since 2024, H5N1 has spread widely among poultry and dairy cows, resulting in dozens of human cases among agricultural workers. While”
evidence, article, points to no. Claim: Farmers and workers resisted testing and monitoring, leaving blind spots in H5N1 spread.